The aim of this study is to draw attention to a rare side effect of PP and contribute to the literature by presenting a case of high fever and high liver function tests after application of the first dose.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Paliperidone palmitate (PP) is a long-acting antipsychotic administered intramuscularly once a month in the acute and maintenance treatments of schizophrenia.
📊
Key Findings & Data:It has been reported to be successful especially in patients with poor oral drug compliance.
💡
Conclusion & Impact:The aim of this study is to draw attention to a rare side effect of PP and contribute to the literature by presenting a case of high fever and high liver function tests after application of the first dose.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Paliperidone palmitate (PP) is a long-acting antipsychotic administered intramuscularly once a month in the acute and maintenance treatments of schizophrenia. It has been reported to be successful especially in patients with poor oral drug compliance. The most common side effects are dizziness, sleepiness, anxiety, injection site reactions, and extrapyramidal system symptoms. The aim of this study is to draw attention to a rare side effect of PP and contribute to the literature by presenting a case of high fever and high liver function tests after application of the first dose.
🔖
Cite This Article
ERDOGAN, E., DELİBAS, D. H. (2020). Development of acute hepatotoxicity following the first dose of paliperidone palmitate: a case report. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 33 - Sayı: 1, 92–95. https://ajindex.com/articles/149141
Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007; 115:260-267
McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006; 67(Suppl 5):15-18
Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 2012; 12:26
Cleton A, Rossenu S, Hough D, Crauwels H, Vandebosch A, Berwaerts J, et al. Evaluation of the pharmacokinetic profile of deltoid versus gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Poster presented at the American Society for Pharmacology and Therapeutics (PI-75). Orlando, FL, 2008 Apr 2-5. Clin Pharmacol Ther 2008; 83:S31 5. Cleton A, Rossenu S, Hough D, Crauwels H, Berwaerts J, Gopal S, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg EG. A new long-acting injectable antipsychotic, following administration in the deltoid or gluteal muscles. Poster presented at American Society for Clinical Pharmacology and Therapeutics (PI-74). Orlando, FL, 2008 Apr 2–5. Clin Pharmacol Ther 2008; 83:S31 6. Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2010; 7:561-572
Kane JM, Barett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004; 65:1447-1455
Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24 (Suppl 1):S7-S14
Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (Suppl 18):36-46
Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010; 25:247-256
Fujii Y. What lessons should we learn from the death of patients on Xeplion? Psychiatry Clin Neurosci 2015; 117:132-45. (Japanese with English abstract
Omi T, Kanai K, Kiguchi T, Nishida T, Fujimi S, Matsunaga H. The possibi